FDA, WebMD expand partnership
This article was originally published in The Tan Sheet
Executive SummaryFDA and WebMD Health Corp. expand their partnership to provide consumers with increased access to FDA's consumer information, the agency says Oct. 29. The second phase of the partnership launched in December 2008 includes additional multimedia tools and content on WebMD's Web site about allergies and asthma, children's health, diabetes, heart health and vitamins and supplements, FDA says. A release says the partnership increased FDA's consumer reach when the agency warned the public to stop using Iovate Pharmaceuticals' weight-loss product Hydroxycut because of serious adverse event reports (1"Health News Daily" May 4, 2009)
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.